Seeking Alpha
Profile| Send Message| ()  
Excerpt from our Wall Street Breakfast, a one-page summary of this morning's key market-moving and stock-moving stories:

Boehringer to Buy Pfizer's Zantac for $509.5 Million [Bloomberg]

Summary: German-owned Boehringer Ingelheim GmbH agreed to buy the U.S. rights to the drug Zantac from Pfizer (PFE) for $509.5 million. The heartburn medication was sold as part of Pfizer's spinoff of its consumer unit -- a move necessary to receive approval from federal antitrust regulators for the overall sale of its consumer health-care business to Johnson & Johnson (JNJ). The sales of Zantac and Pfizer's consumer-health unit are expected to close by the end of the year, according to Johnson & Johnson spokesman Marc Monseau. Monseau declined to comment on whether other product sales would be needed to gain the necessary FTC approval.
Related links: * J&J, Pfizer Unload Zantac * With Pfizer Bigger is Better * Johnson & Johnson — 73 Consecutive Years of Sales Increases! * Drug Companies Threatened By Proposed Patent Legislation * ComCom to Assess Johnson's Pfizer Deal
Potentially impacted stocks and ETFs: Abbott Laboratories (ABT), Bristol Myers Squibb (BMY), Merck (MRK), GlaxoSmithKline (GSK), PowerShares Dynamic Pharmaceutical (PJP), iShares Dow Jones U.S. Pharmaceuticals (IHE)

Seeking Alpha is not affiliated with Bloomberg

Seeking Alpha's Wall Street Breakfast summarizes today's key market- and stock-moving news. Receive it by email every weekday morning (free/no spam).

Comment on this article

Source: Pfizer Sells U.S. Rights to Zantac With Hopes It Can Sell Its Consumer Health Care Unit to Johnson & Johnson